Morpholine → (2-Fluoro-4-iodo-phenyl)-[4-(5-morpholin-4-yl-[1,3,4]oxadiazol-2-yl)-pyridin-3-yl]-amine

HRID 658366Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 658366
[F:1][C:2]1[CH:7]=[C:6]([I:8])[CH:5]=[CH:4][C:3]=1[NH:9][C:10]1[CH:11]=[N:12][CH:13]=[CH:14][C:15]=1[C:16]1[O:17][C:18](SC)=[N:19][N:20]=1.[NH:23]1[CH2:28][CH2:27][O:26][CH2:25][CH2:24]1>O1CCOCC1>[F:1][C:2]1[CH:7]=[C:6]([I:8])[CH:5]=[CH:4][C:3]=1[NH:9][C:10]1[CH:11]=[N:12][CH:13]=[CH:14][C:15]=1[C:16]1[O:17][C:18]([N:23]2[CH2:28][CH2:27][O:26][CH2:25][CH2:24]2)=[N:19][N:20]=1

Komponenten

4

Edukt 2

HCID 8083MorpholineHCID 24890085(2-Fluoro-4-iodo-phenyl)-[4-(5-methylsulfanyl-[1,3,4]oxadiazol-2-yl)-pyridin-3-yl]-amine

Produkt 1

HCID 24890249(2-Fluoro-4-iodo-phenyl)-[4-(5-morpholin-4-yl-[1,3,4]oxadiazol-2-yl)-pyridin-3-yl]-amine

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 312751,4-DioxaneLösungsmittel

Reaktionsbedingungen

Temperatur
120 °C

Versuchsvorschrift

To a solution of (2-Fluoro-4-iodo-phenyl)-[4-(5-methylsulfanyl-[1,3,4]oxadiazol-2-yl)-pyridin-3-yl]-amine (100 mg, 0.23 mmol) in dioxane (5 mL) were added morphline (101 mg, 1.17 mmol). The reaction mixture was stirred at 120° C. for 8 h. The solvent was evaporated, residue was purified with prep plate (CH2Cl2:MeOH=20:1 5% TEA), collected product 24 mg. LC-MS (Method A) [5.20 min; 468(M+1)]

Aufarbeitung

  1. customThe solvent was evaporated
  2. customresidue was purified with prep plate (CH2Cl2:MeOH=20:1 5% TEA)
  3. customcollected product 24 mg
  4. customLC-MS (Method A) [5.20 min; 468(M+1)]

Quellen und Nachweise

ORD-Eintrag
ord-64828edf3229482d9aaa795c05767033
Quelldatensatz
uspto-grants-2011_12
Patentnummer
US08076486B2

Notizen zur Reaktion

Wird geladen…